TCL Archive IL-2 Trials Proliferate; Biotherapeutics Sees NCI Proposal As Vindication Of Its Policies May 8, 1987
TCL Archive Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease December 28, 2012
TCL Archive NCI declined to pay for economic, quality of life analysis in Avastin, Erbitux study. June 3, 2005